Phibro Animal Health (PAHC) Projected to Announce Earnings on Wednesday

Phibro Animal Health (NASDAQ:PAHC) is anticipated to post its Q4 2026 results after the market closes on Wednesday, August 26th. Analysts expect the company to announce earnings of $0.7130 per share and revenue of $381.1760 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Thursday, August 27, 2026 at 9:00 AM ET.

Phibro Animal Health Stock Performance

Shares of NASDAQ:PAHC opened at $36.32 on Monday. The firm has a market cap of $1.47 billion, a PE ratio of 15.59, a price-to-earnings-growth ratio of 0.51 and a beta of 0.46. The firm’s 50 day simple moving average is $33.70 and its 200-day simple moving average is $42.61. Phibro Animal Health has a one year low of $28.25 and a one year high of $60.08. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17.

Phibro Animal Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Wednesday, September 2nd will be issued a $0.12 dividend. The ex-dividend date is Wednesday, September 2nd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.3%. Phibro Animal Health’s payout ratio is presently 20.60%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PAHC. Citigroup dropped their price objective on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Weiss Ratings cut Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. Wall Street Zen downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $42.50.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently added to or reduced their stakes in the stock. State Street Corp raised its holdings in Phibro Animal Health by 5.4% in the fourth quarter. State Street Corp now owns 942,279 shares of the company’s stock worth $35,204,000 after purchasing an additional 48,243 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Phibro Animal Health by 4,227.1% in the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after buying an additional 626,492 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Phibro Animal Health by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock valued at $21,265,000 after buying an additional 21,951 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Phibro Animal Health by 1.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company’s stock worth $18,394,000 after buying an additional 6,826 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Phibro Animal Health by 22.5% in the 3rd quarter. Invesco Ltd. now owns 322,299 shares of the company’s stock worth $13,040,000 after buying an additional 59,226 shares during the last quarter. Institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.